323 related articles for article (PubMed ID: 32660394)
1. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
[TBL] [Abstract][Full Text] [Related]
2. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
4. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
5. Precision care in the treatment of pediatric asthma.
Mahmood L; Keskin S; Jefferson AA
Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
[TBL] [Abstract][Full Text] [Related]
6. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
7. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab for the treatment of asthma.
Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
[TBL] [Abstract][Full Text] [Related]
9. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
[TBL] [Abstract][Full Text] [Related]
10. Biological treatments for severe asthma: where do we stand?
Busse WW
Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397
[TBL] [Abstract][Full Text] [Related]
11. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
[TBL] [Abstract][Full Text] [Related]
12. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
[TBL] [Abstract][Full Text] [Related]
13. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
Pepper AN; Hanania NA; Humbert M; Casale TB
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
[TBL] [Abstract][Full Text] [Related]
14. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management.
Arnold RJ; Massanari M; Lee TA; Brooks E
Manag Care; 2018 Jul; 27(7):34-41. PubMed ID: 29989900
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
[TBL] [Abstract][Full Text] [Related]
17. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function.
Paro-Heitor ML; Bussamra MH; Saraiva-Romanholo BM; Martins MA; Okay TS; Rodrigues JC
Pediatr Pulmonol; 2008 Feb; 43(2):134-41. PubMed ID: 18085692
[TBL] [Abstract][Full Text] [Related]
18. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
Menigoz C; Dirou S; Chambellan A; Hassoun D; Moui A; Magnan A; Blanc FX
J Asthma; 2023 Jun; 60(6):1162-1170. PubMed ID: 36301080
[TBL] [Abstract][Full Text] [Related]
19. Utility of exhaled nitric oxide in the diagnosis and management of asthma.
Majid H; Kao C
Curr Opin Pulm Med; 2010 Jan; 16(1):42-7. PubMed ID: 19797954
[TBL] [Abstract][Full Text] [Related]
20. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
